Hemera
  • Company
    • About us
    • Team
    • Job opportunities
  • Cell therapy
    • REMaST®️
    • Preclinical results
    • Clinical trials
    • Publications
  • Newsroom
    • Highlights
    • News and events
    • Videos
    • Interviews
  • Investors
  • English
    • Italiano (Italian)
Select Page

Hemera Named Finalist at the 2024 Italian Master Startup Award

Sep 6, 2024 | News, Press Releases

We are pleased to announce that Hemera has been selected as one of the 11 finalists for the Italian Master Startup Award (IMSA), the prestigious prize dedicated to scale-ups born from academic research. The award is promoted by the national network of university...

Hemera Presents the Progress of REMaST®️ Therapy at the FENS Forum 2024

Jun 28, 2024 | News, Press Review

We are excited to announce our participation in the FENS Forum 2024, the largest European congress dedicated to neuroscience, taking place from June 25 to 29 in Vienna. The teams from the Therapy Development Department and the Research and Development Department,...

We are pleased to welcome Humanitas Mirasole S.p.A. among Hemera’s shareholders

Jun 27, 2024 | News

We are pleased to announce that Istituto Clinico Humanitas Mirasole S.p.A. has joined Hemera’s shareholding structure, acquiring a 1.5% stake in the company. Humanitas is a highly specialized teaching and research hospital, accredited by the Italian National Health...

Hemera at ISCT 2024: Innovation and Cutting-Edge Cell Therapies

May 28, 2024 | News, Press Review

Hemera enthusiastically participated in ISCT 2024, the event organized by the International Society for Cell & Gene Therapy, held in Vancouver from May 28 to June 2. During this conference, Hemera was present in the Innovation Zone, an area dedicated to the most...

Innovation Coffee: Advancements in REMaST® Therapy and the Mission to Regenerate Nervous Tissue.

Dec 5, 2023 | News

In the context of the “Healing the Incurable” Innovation Coffee, our CEO Cristiana Vignoli enthusiastically shared significant progress in the research of our revolutionary REMaST® therapy in an interview conducted at the Innovation Center of Intesa San...

Scientific Venture Capital Selects Hemera Among Italy’s Most Innovative Deep-Tech Companies

Nov 9, 2023 | News

Significant Recognition for REMaST® Therapy, a New Perspective for Medullo-Injured Patients Hemera has been chosen among the most innovative scientific entrepreneurial initiatives in Italy by the investment holding company Scientific Venture Capital. This firm...
« Older Entries
Next Entries »

Follow us on social:

  • Follow
  • Follow
  • Follow

HÊMERA SRL

Via Giovanni della Casa, 26
37122 Verona – Italy
VAT IT04819260235
REA: VR – 448793
Mail: info@hemerapharma.com
PEC: hemera@pec.it
Web: hemerapharma.com

OPERATIONAL HEADQUARTERS VERONA

Dipartimento di Diagnostica e Sanità pubblica. Palazzina Medicina Legale – Farmacologia – CIRSAL.

Piazzale L. Scuro, 10 – 37134 Verona (VR)

OPERATIONAL HEADQUARTERS MILAN

Dipartimento di Biotecnologie Mediche e Medicina Traslazionale – BIOMETRA. Laboratorio Interdisciplinare di Tecnologie Avanzate (LITA).

Via Fratelli Cervi, 93 – 20054 Segrate (MI)

Privacy Policy | Cookies policy | Modifica preferenze
Copyright Hemera Srl © 2025
FAQ | Contacts